5-氯-N,2-二羟基苯甲酰胺 | 37551-43-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氯-N,2-二羟基苯甲酰胺
• 英文名称: N-(5-chlorosalicyl) hydroxamic acid
• 英文别名: 5-chlorosalicylhydroxamic acid；5-chloro-2,N-dihydroxy-benzamide；5-chloro-2-hydroxy-benzohydroxamic acid；H3Clshi；5-Chlor-2-hydroxy-benzohydroxamsaeure；5-Chlor-salicylhydroxamsaeure；5-chloro-N,2-dihydroxybenzamide
• CAS: 37551-43-2
• 化学式: C₇H₆ClNO₃
• mdl: MFCD00203857
• 分子量: 187.583
• InChiKey: VGDCRPRQQPVICX-UHFFFAOYSA-N

物化性质

• 熔点：
  246 °C
• 密度：
  1.548±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2924299090
• 储存条件：
  存储条件为2-8°C，并需保存在惰性气体中。

SDS

Name:	5-Chloro-N 2-dihydroxybenzamide 97% Material Safety Data Sheet
Synonym:	5-Chloro-2-hydroxybenzohydroxamic acid5-Chlorosalicylhydroxamic aci
CAS:	37551-43-2

Section 1 - Chemical Product MSDS Name:5-Chloro-N 2-dihydroxybenzamide 97% Material Safety Data Sheet
Synonym:5-Chloro-2-hydroxybenzohydroxamic acid5-Chlorosalicylhydroxamic aci

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
37551-43-2	5-Chloro-N,2-dihydroxybenzamide	97%	253-550-0

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 37551-43-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 208 - 212 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H6ClNO3
Molecular Weight: 188

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 37551-43-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Chloro-N,2-dihydroxybenzamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 37551-43-2: No information available.
Canada
CAS# 37551-43-2 is listed on Canada's NDSL List.
CAS# 37551-43-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 37551-43-2 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-N,2-二羟基苯甲酰胺 在 氯化亚砜 作用下， 生成 氯唑沙宗
  参考文献：
  名称：

  BUU-HOI; DAT XUONG; HOANG NAM, Comptes rendus hebdomadaires des seances de l'Academie des sciences, 1953, vol. 236, # 6, p. 635 - 637

  摘要：

  DOI：
• 作为产物：
  描述：

  5-氯代水杨酸 在 sodium hydroxide 、 硫酸 、 硫酸羟胺 作用下， 以 甲醇 、 水 为溶剂， 以84.6%的产率得到5-氯-N,2-二羟基苯甲酰胺
  参考文献：
  名称：

  Chemical process for preparation of

  摘要：

  该化合物7-氯-2-甲基-3,3a-二氢-2H,9H-异噁唑啉(3,2-b)(1,3)-苯并噁唑啉-9-酮是通过将四氢呋喃和巴豆醛与5-氯水杨酰羟肟酸混合物反应制得的。该化合物已经证明具有利尿酸排泄剂的作用。

  公开号：

  US04224443A1

文献信息

• 2,3,4,4A-Tetrahydro-10H-1,2-oxazino[3,2-b](1,3)benzoxazin-10-ones
  申请人：Carter-Wallace, Inc.

  公开号：US04024139A1

  公开（公告）日：1977-05-17

  Chemical compounds of the formula: ##STR1## wherein X is hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy, nitro, amino, acetamido, sulfonamido or trifluoromethyl, and each R is selected from the group consisting of hydrogen and lower alkyl. Said compounds have valuable anti-inflammatory activity in standard laboratory animals.

  化学式为：##STR1## 其中 X 为氢、羟基、卤素、低烷基、低烷氧基、硝基、氨基、乙酰胺基、磺胺基或三氟甲基，每个 R 选自氢和低烷基的化合物在标准实验动物中具有有价值的抗炎活性。
• Benzo[d]isoxazol-3-ol DAAO inhibitors
  申请人：Fang Kevin Q.

  公开号：US20050143434A1

  公开（公告）日：2005-06-30

  Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutic amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein Z 1 is N or CR 3 ; Z 2 is N or CR 4 ; Z 3 is O or S; A is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc or a mixture thereof; R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, alkyl, hydroxy alkoxy, aryl, acyl, halo, cyano, haloalkyl, NHCOOR 5 and SO 2 NH 2 ; R 5 is aryl, arylalkyl, heteroaryl or heteroarylalkyl; at least one of R 1 , R 2 , R 3 and R 4 is other than hydrogen; and at least one of Z 1 and Z 2 is other than N.

  增加D-丝氨酸浓度和减少D-丝氨酸氧化有毒产物浓度的方法，用于增强学习、记忆和/或认知，或用于治疗精神分裂症、阿尔茨海默病、共济失调、或神经病性疼痛，或预防神经退行性疾病特征性的神经元功能丧失，包括向需要治疗的受试者施用化合物I的治疗量，或其药学上可接受的盐或溶剂：其中Z1为N或CR3；Z2为N或CR4；Z3为O或S；A为氢、烷基或M+；M为铝、钙、锂、镁、钾、钠、锌或其混合物；R1、R2、R3和R4独立地选择自氢、烷基、羟基烷氧基、芳基、酰基、卤素、氰基、卤代烷基、NHCOOR5和SO2NH2；R5为芳基、芳基烷基、杂环芳基或杂环芳基烷基；R1、R2、R3和R4中至少有一个不是氢；且Z1和Z2中至少有一个不是N。
• Method for lowering serum uric acid
  申请人：Carter-Wallace, Inc.

  公开号：US04224323A1

  公开（公告）日：1980-09-23

  A method for lowering serum uric acid is disclosed which comprises administering to a human for its uricosuric activity a pharmaceutical composition comprising 7-chloro-2-methyl-3,3a-dihydro-2H,9H-isoxazolo (3,2-b) (1,3)-benzoxazin-9-one. 7-chloro-2-methyl-3,3a-dihydro-2H,9H-isoxazolo (3,2-b) (1,3) benzoxazin-9-one is a useful compound having valuable pharmacological properties, for example, it is a valuable anti-inflammatory agent, as evidenced by its ability to inhibit the local edema formation characteristic of inflammatory states when administered systemically to warm-blooded animals.

  揭示了一种降低血清尿酸的方法，包括向人体施用一种药物组合物，其中包括7-氯-2-甲基-3,3a-二氢-2H,9H-异噁唑啉(3,2-b)(1,3)-苯并噁唑啉-9-酮，以发挥其利尿活性。7-氯-2-甲基-3,3a-二氢-2H,9H-异噁唑啉(3,2-b)(1,3)-苯并噁唑啉-9-酮是一种有价值的化合物，具有有价值的药理特性，例如，它是一种有价值的抗炎药物，其通过系统给温血动物施用时能够抑制炎症状态下的局部水肿形成。
• Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents
  作者：Joseph P. Yevich、James S. New、David W. Smith、Walter G. Lobeck、John D. Catt、Joseph L. Minielli、Michael S. Eison、Duncan P. Taylor、Leslie A. Riblet、Davis L. Temple

  DOI：10.1021/jm00153a010

  日期：1986.3

  Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens. Structure-activity relationships within the series are discussed. Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests. It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h. The compound's lack of typical neuroleptic-like effects in the rat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy. Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile. Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.
• Reisner; Ludwig; Stiefel, Arzneimittel-Forschung/Drug Research, 1977, vol. 27, # 4, p. 760 - 766
  作者：Reisner、Ludwig、Stiefel、Gister、Meyer、Powell、Sofia

  DOI：——

  日期：——